Month: November 2025

The biologic drug market is one of the most lucrative in the world, but as patents expire, a new champion emerges: the biosimilar. These are not simple generics; they are…

For a limited time, patients in the US can get the first two doses of authentic, FDA-approved Wegovy® and Ozempic® for only $199 each beginning November 17, 2025 Also effective…

Many early stage biotechnology companies face challenges in securing funding. The biotechnology sector is highly competitive, and capital has been scarce in the last few years, leading some companies to…

The competitive landscape for biosimilar therapies targeting bone health and cancer-related skeletal events shifted markedly in fall 2025, as the FDA approved multiple denosumab biosimilars and issued 2 new interchangeability…

Advances in glycosylation control, plant engineering, and rapid-expression systems are redefining what’s possible for plant-made drugs and vaccines. Early in the COVID-19 pandemic, Canadian biotechnology company Medicago began clinical trials…